Ramy Riad Ahmed Ibrahim Sells 7,277 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Ramy Riad Ahmed Ibrahim sold 7,277 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $124,436.70. Following the completion of the sale, the insider owned 102,588 shares of the company’s stock, valued at approximately $1,754,254.80. This trade represents a 6.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.0%

NYSE TAK opened at $17.41 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The company has a market capitalization of $55.77 billion, a price-to-earnings ratio of 51.19 and a beta of -0.08. The company’s fifty day moving average price is $16.53 and its two-hundred day moving average price is $17.14.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, research analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership raised its position in shares of Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. UBS Group AG boosted its position in Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd increased its position in Takeda Pharmaceutical by 407.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp lifted its stake in Takeda Pharmaceutical by 98.4% in the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after buying an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after acquiring an additional 880,289 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Takeda Pharmaceutical News Roundup

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.